Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~All Participants:~-Judged to be in good physical health on the basis of medical history, physical examination and laboratory results~Boys and Girls 9 to 14 Years:~-Must not have had coitarche and does not plan on becoming sexually active during the vaccination period~Women 16 to 26 Years:~* Has never had a Papanicolaou (Pap) test or only had normal Pap test results~* A lifetime history of 0 to 4 male and/or female sexual partners~Exclusion Criteria:~All Participants:~* Known allergy to any vaccine component~* History of severe allergic reaction that required medical intervention~* Thrombocytopenia or any coagulation disorder~* Females only: participant is pregnant or expecting to donate eggs during day 1 through month 7~* Currently immunocompromised, or been diagnosed with immunodeficiency~* Had a splenectomy~* Receiving or has received immunosuppressive therapies within the last year~* Received any immunoglobulin product or blood-derived product within 3 months~* Received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- Girls 9 to 14 Years V503 at Months 0 and 6 (Type: EXPERIMENTAL): Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
- Boys 9 to 14 Years V503 at Months 0 and 6 (Type: EXPERIMENTAL): Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
- Girls and Boys 9 to 14 Years V503 at Months 0 and 12 (Type: EXPERIMENTAL): Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.
- Girls 9 to 14 Years V503 at Months 0, 2, and 6 (Type: EXPERIMENTAL): Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
- Young Women 16 to 26 Years V503 at Months 0, 2, and 6 (Type: ACTIVE_COMPARATOR): Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.

Based on this trial design, predict the completion outcome and termination type (if applicable).